Scrambled prion domains form prions and amyloid

Molecular and Cellular Biology

Volumn 24, Issue 16, 2004, Pages 7206-7213

  Ross, Eric D ^a   Baxa, Ulrich ^a,b   Wickner, Reed B ^a,c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; ASPARAGINE; FUNGAL PROTEIN; GLUTAMINE; PRION PROTEIN; PROTEIN RNQ1P; PROTEIN SUP35P; PROTEIN URE2P; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; SACCHAROMYCES CEREVISIAE; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACIDS; AMYLOID; HUMANS; MOLECULAR SEQUENCE DATA; PRIONS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RANDOM ALLOCATION; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SEQUENCE ALIGNMENT;

SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 3543022080     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.16.7206-7213.2004     Document Type: Article

References (50)

1. Bauer, H. H., U. Aebi, M. Haner, R. Hermann, M. Muller, and H. P. Merkle. 1995. Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J. Struct. Biol. 115:1-15.
2. Baxa, U., V. Speransky, A. C. Steven, and R. B. Wickner. 2002. Mechanism of inactivation on prion conversion of the Saccharomyces cerevisiae Ure2 protein. Proc. Natl. Acad. Sci. USA 99:5253-5260.
3. Baxa, U., K. L. Taylor, J. S. Wall, M. N. Simon, N. Cheng, R. B. Wickner, and A. C. Steven. 2003. Architecture of Ure2p prion filaments: the N-terminal domains form a central core fiber. J. Biol. Chem. 278:43717-43727.
4. Borchsenius, A. S., R. D. Wegrzyn, G. P. Newnam, S. G. Inge-Vechtomov, and Y. O. Chernoff. 2001. Yeast prion protein derivative defective in aggregate shearing and production of new "seeds." EMBO J. 20:6683-6691.
5. Bousset, L., H. Belrhali, J. Janin, R. Melki, and S. Morera. 2001. Structure of the globular region of the prion protein Ure2 from the yeast Saccharomyces cerevisiae. Structure 9:39-46.
6. Bousset, L., N. H. Thomson, S. E. Radford, and R. Melki. 2002. The yeast prion Ure2p retains its native alpha-helical conformation upon assembly into protein fibrils in vitro. EMBO J. 21:2903-2911.
7. Chiti, F., M. Stefani, N. Taddei, G. Ramponi, and C. M. Dobson. 2003. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424:805-808.
8. Conde, J., and G. R. Fink. 1976. A mutant of Saccharomyces cerevisiae defective for nuclear fusion. Proc. Natl. Acad. Sci. USA 73:3651-3655.
9. Cooper, T. G. 2002. Transmitting the signal of excess nitrogen in Saccharomyces cerevisiae from the Tor proteins to the GATA factors: connecting the dots. FEMS Microbiol. Rev. 26:223-238.
10. Cox, B. S. 1965. PSI, a cytoplasmic suppressor of super-suppressor in yeast. Heredity 26:211-232.
11. DePace, A. H., A. Santoso, P. Hillner, and J. S. Weissman. 1998. A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion. Cell 93:1241-1252.
12. Derkatch, I. L., M. E. Bradley, J. Y. Hong, and S. W. Liebman. 2001. Prions affect the appearance of other prions: the story of [PIN(+)J. Cell 106:171-182.
13. Dobson, C. M. 1999. Protein misfolding, evolution, and disease. Trends Biochem. Sci. 24:329-332.
14. Doel, S. M., S. J. McCready, C. R. Nierras, and B. S. Cox. 1994. The dominant PNM2- mutation which eliminates the psi factor of Saccharomyces cerevisiae is the result of a missense mutation in the SUP35 gene. Genetics 137:659-670.
15. Edskes, H. K., V. T. Gray, and R. B. Wickner. 1999. The [URE3] prion is an aggregated form of Ure2p that can be cured by overexpression of Ure2p fragments. Proc. Natl. Acad. Sci. USA 96:1498-1503.
16. Edskes, H. K., and R. B. Wickner. 2000. A protein required for prion generation: [URE3] induction requires the Ras-regulated Mks1 protein. Proc. Natl. Acad. Sci. USA 97:6625-6629.
17. Ferreira, P. C., F. Ness, S. R. Edwards, B. S. Cox, and M. F. Tuite. 2001. The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation. Mol. Microbiol. 40:1357-1369.
18. Goldsbury, C. S., G. J. Cooper, K. N. Goldie, S. A. Muller, E. L. Saafi, W. T. Gruyters, M. P. Misur, A. Engel, U. Aebi, and J. Kistler. 1997. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119:17-27.
19. Hurle, M. R., L. R. Helms, L. Li, W. Chan, and R. Wetzel. 1994. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad. Sci. USA 91:5446-5450.
20. Jung, G., G. Jones, and D. C. Masison. 2002. Amino acid residue 184 of yeast Hsp104 chaperone is critical for prion-curing by guanidine, prion propagation, and thermotolerance. Proc. Natl. Acad. Sci. USA 99:9936-9941.
21. Jung, G., and D. C. Masison. 2001. Guanidine hydrochloride inhibits Hsp104 activity in vivo: a possible explanation for its effect in curing yeast prions. Curr. Microbiol. 43:7-10.
22. Kelly, J. W. 1998. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8:101-106.
23. Kisilevsky, R., and P. E. Fraser. 1997. A beta amyloidogenesis: unique, or variation on a systemic theme? Crit. Rev. Biochem. Mol. Biol. 32:361-404.
24. Lacroute, F. 1971. Non-Mendelian mutation allowing ureidosuccinic acid uptake in yeast. J. Bacteriol. 106:519-522.
25. Liebman, S. W., and I. L. Derkatch. 1999. The yeast [PSI+] prion: making sense of nonsense. J. Biol. Chem. 274:1181-1184.
26. Liemann, S., and R. Glockshuber. 1999. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 38:3258-3267.
27. Maddelein, M. L., and R. B. Wickner. 1999. Two prion-inducing regions of Ure2p are nonoverlapping. Mol. Cell. Biol. 19:4516-4524.
28. Masison, D. C., M. L. Maddelein, and R. B. Wickner. 1997. The prion model for [URE3] of yeast: spontaneous generation and requirements for propagation. Proc. Natl. Acad. Sci. USA 94:12503-12508.
29. Masison, D. C., and R. B. Wickner. 1995. Prion-inducing domain of yeast Ure2p and protease resistance of Ure2p in prion-containing cells. Science 270:93-95.
30. McCutchen, S. L., Z. Lai, G. J. Miroy, J. W. Kelly, and W. Colon. 1995. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34:13527-13536.
31. Michelitsch, M. D., and J. S. Weissman. 2000. A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Proc. Natl. Acad. Sci. USA 97:11910-11915.
32. Ness, F., P. Ferreira, B. S. Cox, and M. F. Tuite. 2002. Guanidine hydrochloride inhibits the generation of prion "seeds" but not prion protein aggregation in yeast. Mol. Cell. Biol. 22:5593-5605.
33. Ochman, H., A. S. Gerber, and D. L. Haiti. 1988. Genetic applications of an inverse polymerase chain reaction. Genetics 120:621-623.
34. Paushkin, S. V., V. V. Kushnirov, V. N. Smirnov, and M. D. Ter-Avanesyan. 1996. Propagation of the yeast prion-like [psi+] determinant is mediated by oligomerization of the SUP35-encoded polypeptide chain release factor. EMBO J. 15:3127-3134.
35. Perrett, S., S. J. Freeman, P. J. Butler, and A. R. Fersht. 1999. Equilibrium folding properties of the yeast prion protein determinant Ure2. J. Mol. Biol. 290:331-345.
36. Ridley, S. P., S. S. Sommer, and R. B. Wickner. 1984. Superkiller mutations in Saccharomyces cerevisiae suppress exclusion of M2 double-stranded RNA by L-A-HN and confer cold sensitivity in the presence of M and L-A-HN. Mol. Cell. Biol. 4:761-770.
37. Ripaud, L., L. Maillet, and C. Cullin. 2003. The mechanisms of [URE3] prion elimination demonstrate that large aggregates of Ure2p are dead-end products. EMBO J. 22:5251-5259.
38. Roberts, B. T., and R. B. Wickner. 2003. Heritable activity: a prion that propagates by covalent autoactivation. Genes Dev. 17:2083-2087.
39. Santoso, A., P. Chien, L. Z. Osherovich, and J. S. Weissman. 2000. Molecular basis of a yeast prion species barrier. Cell 100:277-288.
40. Sherman, F. 1991. Getting started with yeast. Methods Enzymol. 194:3-21.
41. Sipe, J. D., and A. S. Cohen. 2000. Review: history of the amyloid fibril. J. Struct. Biol. 130:88-98.
42. Sondheimer, N., and S. Lindquist. 2000. Rnq1: an epigenetic modifier of protein function in yeast. Mol. Cell 5:163-172.
43. Speransky, V. V., K. L. Taylor, H. K. Edskes, R. B. Wickner, and A. C. Steven. 2001. Prion filament networks in [URE3] cells of Saccharomyces cerevisiae. J. Cell Biol. 153:1327-1336.
44. Taylor, K. L., N. Cheng, R. W. Williams, A. C. Steven, and R. B. Wickner. 1999. Prion domain initiation of amyloid formation in vitro from native Ure2p. Science 283:1339-1343.
45. Ter-Avanesyan, M. D., A. R. Dagkesamanskaya, V. V. Kushnirov, and V. N. Smirnov. 1994. The SUP35 omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi+] in the yeast Saccharomyces cerevisiae. Genetics 137:671-676.
46. Tuite, M. F., C. R. Mundy, and B. S. Cox. 1981. Agents that cause a high frequency of genetic change from [psi+] to [psi-] in Saccharomyces cerevisiae. Genetics 98:691-711.
47. Turoscy, V., and T. G. Cooper. 1987. Ureidosuccinate is transported by the allantoate transport system in Saccharomyces cerevisiae. J. Bacteriol. 169:2598-2600.
48. Umland, T. C., K. L. Taylor, S. Rhee, R. B. Wickner, and D. R. Davies. 2001. The crystal structure of the nitrogen regulation fragment of the yeast prion protein Ure2p. Proc. Natl. Acad. Sci. USA 98:1459-1464.
49. Wegrzyn, R. D., K. Bapat, G. P. Newnam, A. D. Zink, and Y. O. Chernoff. 2001. Mechanism of prion loss after Hsp104 inactivation in yeast. Mol. Cell. Biol. 21:4656-4669.
50. Wickner, R. B. 1994. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264:566-569.